Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France

Piercy, James; Ryan, James A.; Megas, Françoise

doi:10.3111/200407001018

Cited by 9 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If we consider international CE evaluations, 14 , 16 , 18 , 20 our results still remain in a highly plausible range. A French model by Piercy et al.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Capri

Barbieri

Waure

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

ABSRACTIn the perspective of reaching at least 75% influenza vaccination coverage in the elderly and substantial budget constraints, Italian decision makers are facing important challenges in determining an optimal immunization strategy for this growing and particularly vulnerable population. Four different influenza vaccines are currently available for Italian older adults aged 65 years or above, namely trivalent inactivated vaccines (TIVs), MF59-adjuvanted TIV (MF59-TIV), intradermal TIV (ID-TIV) and quadrivalent inactivated vaccines (QIVs). The present study is the first to compare the cost-effectiveness profiles of virtually all possible public health strategies, including the aforementioned four vaccine formulations as well non-vaccination. For this purpose, a decision tree model was built ex novo; the analysis was conducted from the third-payer perspective in the timeframe of one year. All available vaccines were cost-effective compared with non-vaccination. However, MF59-TIV had the most favorable economic profile in the Italian elderly population. Indeed, compared with non-vaccination, it was deemed highly cost-effective with an incremental cost-effectiveness ratio (ICER) of €10,750 per quality-adjusted life year (QALY). The ICER was much lower (€4,527/QALY) when MF59-TIV was directly compared with TIV. ID-TIV and QIV were dominated by MF59-TIV as the former comparators were associated with greater total costs and lower health benefits. Both deterministic and probabilistic sensitivity analyses confirmed robustness of the base case results. From the economic perspective, MF59-TIV should be considered as a preferential choice for Italian older adults aged 65 years or above.

show abstract

“…If we consider international CE evaluations, 14 , 16 , 18 , 20 our results still remain in a highly plausible range. A French model by Piercy et al.…”

Section: Discussionmentioning

confidence: 77%

“… 10 – 13 ). Twenty years of widespread use in the general population, regulatory approval in approximately 30 countries, and several economic evaluations, 14–20 have all established a favorable economic profile of MF59-TIV.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Capri

Barbieri

Waure

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Six studies included administration costs. 25 26 28–31 The total cost of vaccination varied from €8.50 to €35.95 per person, and differences between studies mainly occurred due to variation in administration costs rather than variation in vaccine cost; lower costs were associated with opportunistic vaccination. Transportation costs, over-the-counter medication costs and private nursing home costs were considered in the societal perspective of one study.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union

2017

View full text Add to dashboard Cite

ObjectivesThe Council of the European Union (EU) has recommended that action should be taken to increase influenza vaccination in the elderly population. The aims were to systematically review and critically appraise economic evaluations for influenza vaccination in the elderly population in the EU.MethodsElectronic searches of the NHS Economic Evaluation, Health Technology Assessment, MEDLINE and Embase databases were run to identify full economic evaluations. Two levels of screening were used, with explicit inclusion criteria applied by two independent reviewers at each stage. Prespecified data extraction and critical appraisal were performed on identified studies. Results were summarised qualitatively.ResultsOf the 326 search results, screening identified eight relevant studies. Results varied widely, with the incremental cost-effectiveness ratio ranging from being both more effective and cheaper than no intervention to costing €4 59 350 per life-year gained. Cost-effectiveness was most sensitive to variations in influenza strain, vaccination type and strategy, population and modelling characteristics.ConclusionsMost studies suggest that vaccination is cost-effective (seven of eight studies identified at least one cost-effective scenario). All but one study used economic models to synthesise data from different sources. The results are uncertain due to the methods used and the relevance and robustness of the data used. Sensitivity analysis to explore these aspects was limited. Integrated, controlled prospective clinical and economic evaluations and surveillance data are needed to improve the evidence base. This would allow more advanced modelling techniques to characterise the epidemiology of influenza more accurately and improve the robustness of cost-effectiveness estimates.

show abstract

“…Therefore, the public decision maker has to face a strategic problem when deciding whether to implement a vaccination campaign and which vaccine(s) to prescribe. Compared with standard nonadjuvanted vaccination, the potential additional benefits of the MF59 adjuvanted vaccine are based on improvement in immunogenicity which results in this flu vaccine being highly cost effective, and vaccination has been shown to be the most cost-effective method of preventing influenza [21].…”

Section: Baio Pammolli Baldo and Trivellomentioning

confidence: 99%

“…The model used in this study is a translation in terms of an OOID of the work of [31], which has been used as an epidemiological basis for other pharmacoeconomics studies [21]. In particular, the authors extended the basic model in order to consider probabilistic rather than deterministic relationships among the variables involved.…”

Section: Object-oriented Influence Diagram For the Influenza Problemmentioning

confidence: 99%

Object-oriented influence diagram for cost–effectiveness analysis of influenza vaccination in the Italian elderly population

Baio

Pammolli

Baldo

et al. 2006

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Influenza infection is a major cause of illness, morbidity and mortality throughout the world, mainly amongst the elderly. Since vaccination has proven to be effective in the reduction of all acute complications, deciding whether to implement a vaccination campaign and which vaccine to prescribe is an important task. The aim of this review is to build a decision model, which allows the decision makers to evaluate the possible results under different scenarios, and to choose the decision associated with the highest expected utility. The analysis is based on Bayesian networks methodology. Vaccination is more effective in the long run and is cost saving compared with the null option. Moreover, the innovative MF59 adjuvanted flu vaccine proves to be cost effective with respect to standard vaccines.

show abstract

Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France

Cited by 9 publications

References 30 publications

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union

Object-oriented influence diagram for cost–effectiveness analysis of influenza vaccination in the Italian elderly population

Contact Info

Product

Resources

About